Professor Camille Carroll
| A programme evaluation of 'First Steps': A peer-conceived, developed and led self-management intervention for people after a Parkinson's diagnosis | 2024 |
|
Professor Camille Carroll
Professor Lynn Rochester
| Accelerating Parkinson’s Disease drug development with federated learning approaches | 2024 |
|
Professor Camille Carroll
| Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease | 2024 |
|
Dr Marie-Louise Zeissler
Sally Collins
Professor Camille Carroll
| Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol | 2024 |
|
Dr Mark Cookson
Professor Camille Carroll
| Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative | 2024 |
|
Professor Camille Carroll
| A modular, deep learning-based holistic intent sensing system tested with Parkinson’s disease patients and controls | 2023 |
|
Professor Camille Carroll
| An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson's Disease Trials | 2023 |
|
Katie Bounsall
Madison Milne-Ives
Professor Camille Carroll
Professor Edward Meinert
| Artificial Intelligence Applications for Assessment, Monitoring, and Management of Parkinson Disease Symptoms: Protocol for a Systematic Review | 2023 |
|
Professor Camille Carroll
| Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9) | 2023 |
|
Professor Camille Carroll
| Blood biomarker-based classification study for neurodegenerative diseases | 2023 |
|
Professor Camille Carroll
| Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study | 2023 |
|
Professor Camille Carroll
| Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1) | 2023 |
|
Professor Camille Carroll
| Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2) | 2023 |
|
Professor Lynn Rochester
Professor Camille Carroll
| Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials | 2023 |
|
Dr Rufus Akinyemi
Professor Camille Carroll
| Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study | 2023 |
|
Professor Camille Carroll
Professor Edward Meinert
| Impact of digital technologies on self-efficacy in people with Parkinson's: a scoping review protocol | 2023 |
|
Professor Camille Carroll
| Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson's disease: A mixed methods protocol | 2023 |
|
Dr Marie-Louise Zeissler
Professor Camille Carroll
| Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol | 2023 |
|
Professor Lynn Rochester
Dr Marie-Louise Zeissler
Professor Camille Carroll
| Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative | 2023 |
|
Dr Marie-Louise Zeissler
Professor Camille Carroll
Professor Lynn Rochester
Professor Alison Yarnall
Sally Collins
et al. | Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease | 2023 |
|
Professor Camille Carroll
| Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease | 2022 |
|
Professor Camille Carroll
| Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT | 2022 |
|
Professor Camille Carroll
| Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT | 2022 |
|
Professor Camille Carroll
| Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial | 2022 |
|
Madison Milne-Ives
Professor Camille Carroll
Professor Edward Meinert
| Self-management Interventions for People With Parkinson Disease: Scoping Review | 2022 |
|
Professor Edward Meinert
Professor Camille Carroll
| The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study | 2022 |
|
Professor Camille Carroll
| Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future? | 2021 |
|
Professor Camille Carroll
| Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines | 2021 |
|
Professor Camille Carroll
| Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease | 2021 |
|
Professor Camille Carroll
| Co-designing Resources for Knowledge-Based Self-reflection for People Living with Parkinson’s Disease to Better Enable Independent Living | 2019 |
|
